2024. Deucravacitinib Long-Term Efficacy Through 4 years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program. SKIN The Journal of Cutaneous Medicine. 8, 4 (Jul. 2024), s408. DOI:https://doi.org/10.25251/skin.8.supp.408.